Neurology
Alzheimer's Disease
Expert Roundtables Podcast: Current Considerations in Diagnosing and Staging Alzheimer’s Disease
Diagnosing and staging patients who are suspected of having Alzheimer’s disease (AD) have long proved challenging. Recent updates in the understanding of the biological aspects of AD have facilitated changes in the way that clinicians identify patients with the disease. Biomarkers, in particular, along with presenting symptoms, are allowing for earlier and more accurate diagnoses, which, in turn, translate to improvements in treatment.
Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143-5169. doi:10.1002/alz.13859
Jack CR Jr, Andrews SJ, Beach TG, et al. Revised criteria for the diagnosis and staging of Alzheimer’s disease. Nat Med. 2024;30(8):2121-2124. doi:10.1038/s41591-024-02988-7
Rabinovici GD, Knopman DS, Arbizu J, et al. Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimers Dement. 2025;21(1):e14338. doi:10.1002/alz.14338
Schneider JA. Neuropathology of dementia disorders. Continuum (Minneap Minn). 2022;28(3):834-851. doi:10.1212/CON.0000000000001137
Schöll M, Vrillon A, Ikeuchi T, et al. Cutting through the noise: a narrative review of Alzheimer’s disease plasma biomarkers for routine clinical use. J Prev Alzheimers Dis. Published online January 14, 2025. doi:10.1016/j.tjpad.2024.100056
Shakir MN, Dugger BN. Advances in deep neuropathological phenotyping of Alzheimer disease: past, present, and future. J Neuropathol Exp Neurol. 2022;81(1):2-15. doi:10.1093/jnen/nlab122
